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Abstract. We developed a method of quantification of the new antidiabetic drug  
3-(1h-benzimidazole-2-yl)-1,2,2-trimethyl-cyclopentane-carbonic acid (c7070) in the blood 
plasma of rats by high-performance liquid chromatography with mass-spectrometric detection. 
The analytical range of the method was 0.02-3876.0 μg in 1 ml of blood plasma. The research 
was partially supported by the grant of the President of the Russian Federation  
№ MD-4711.2015.7  and МК-6135.2016.4. 
Keywords: antidiabetic agent; С7070; the blood plasma of rats; high-performance liquid 
chromatography; mass spectrometric detection; validation.  
 
According to the State Register as of January 1, 
2012, more than 3 million 540 thousand patients with 
diabetes mellitus (DM), 90% of them – with type 2 
diabetes were registered in the Russian Federation. 
However, results of control and epidemiological studies 
of the Endocrinology Research Center, conducted in 
2005-2010, as well as WHO’s data for 2010 indicate 
that the actual number of diabetic patients exceeds the 
registered one by more than 3 times [1]. 
Considering this, the development of new and 
effective drugs for the treatment of DM is one of the 
urgent problems of modern medicine. As it is known, 
the development itself is impossible without studying 
the pharmacokinetics, which accurate assessment 
requires a sensitive and highly-selective method. 
Currently, the reference method for studying the 
pharmacokinetics is a high-performance liquid 
chromatography with mass spectrometry [1, 3, 4]. 
Subject to the above, the objective of the study is 
to develop and validate a method of quantification of 
C7070 by high-performance liquid chromatography 
with mass-spectrometry (HPLC-MS/MS).  
Experimental part.  
Reagents used in this study are the follows: 
C7070 (CJSC "VladMiVa”, Belgorod), fabomotizole 
(Sigma), formic acid (Panreac), ammonium acetate 
(Panreac), methanol (Merk) acetonitrile for gradient 
chromatography (Merk), water purified and 
deionized with “Gene Pure” system (Thermo 
Scientific, USA). 
Identification of C7070 in rat plasma was carried 
out with a liquid chromatograph UltiMate 3000 LC 
(Thermo Fisher Scientific, USA) equipped with a 
thermostated automatic dispenser, vacuum degasser, 
gradient pump, and column thermostat. Detection of 
the analyte was carried out with a mass-spectrometer 
Velos Pro (Thermo Scientific, USA) under ionization 
in the heated electrospray (H-ESI-II).  
Sample preparation. 
Preparation of C7070 solutions involved several 
stages. At the first stage, stock solution of C7070 was 
prepared in methanol at a concentration of 0.2%. At 
the second stage, C7070 solutions with methanol 
were prepared by a series of dilutions of stock 
solution to be further added to standard solutions and 
control solutions at a concentration of 0.00002%, 
0.002% and 0.011%.  
Fabomotizole solutions (internal standard) in 
methanol for introducing into standard and test 
solutions were prepared at the same concentration 
level – 0.1% solution. 
The study used standard samples of C7070 
(CJSC "VladMiVa”, Belgorod), and fabomotizole 
(Sigma). 
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The solutions for the construction of calibration 
curve, in accordance with modern requirements 
[5, 6, 7], were prepared at seven concentration levels 
(0.02 μg, 0.2 μg, 2.00 μg, 1.94 μg, 193.80 μg, 1938.00 
μg and 3876.00 μg in 1 ml plasma). For this purpose, 
100 μl of plasma were placed in 1.5 ml Eppendorf 
tubes, then added aliquots of stock solutions, 100 μl of 
internal standard solution and 100 μl of acetonitrile. 
Then the analyte was extracted in an ultrasonic bath for 
three minutes. The samples were then frozen at -70ºC. 
After defrosting, samples were centrifuged at 13,000 
rev/min and a temperature of 4°C for 25 minutes. The 
supernatant was decanted and analyzed.  
Test solutions were prepared similarly to the 
solutions for the calibration curve based on four 
levels of concentration in five repetitions: 0.02 μg 
(lower limit of quantification – LLOQ), 0.20 μg 
(lower quality control – LQC), 19.38 μg (mean 
control quality – MQC) and 1938.00 μg (upper 
quality control – UQC) in 1 ml of plasma. 
Solutions for the determination of matrix effect 
were prepared similarly to test solutions, but with 
replacing plasma with water [8]. 
Chromatographic separation was performed on a 
150×3.0 mm column filled with converted-phase 
sorbent Zorbax Eclipce XDB C18 with particle size of 
3.0 µm and with a 12.5×3.0 mm guard column Zorbax 
Eclipce XDB C18 with a particle size of 5.0 µm at a 
temperature of 40°C. The chromatographic analysis was 
performed with the use of UltiMate 3000 LC system 
coupled with a mass spectrometric detector under the 
following chromatographic conditions: 
 
Sample volume: 2 µl 
Mobile phase: 
Time, 
 min 
flow,  
ml/min 
5 mM Ammonium 
acetate + 
0.1% formic acid 
Acetonitrile
, % 
 
Methanol, 
 % 
0 0.4 80 20 0 
5.0 0.4 80 20 0 
8.5 0.4 65 10 10 
9.0 0.4 20 70 10 
11.0 0.4 20 70 10 
11.1 0.4 80 20 0 
12.5 0.4 80 20 0 
 
Approximate retention times: С7070 – about 4.7 min;  
Internal Standard (Fabomotizole) – about 8.5 min. 
Injection time: 12.5 min 
Ionization type: H-ESI  
Polarity: С7070 “+” 
Internal Standard (Fabomotizole) “+” 
Mass transition: С7070 – 272.35→255.15; 
Internal Standard (Fabomotizole) – 307.41→114. 
Collision energy: С7070 – 42; 
 Internal Standard (Fabomotizole) – 19  
Source voltage (V): С7070 – 3000 
Internal Standard (Aminophylline) – 3000 
Source temperature (ºC): С7070 –300 
Internal Standard (Fabomotizole) – 300 
Capillary temperature (ºC): С7070 – 350 
Internal Standard (Fabomotizole) – 350 
Sheath gas pressure (Arb):  
С7070 – 60 
Internal Standard (Fabomotizole) – 60 
Aux gas pressure (Arb):  С7070 – 20 
Internal Standard (Fabomotizole) – 20 
 
Results and discussion: 
We developed a highly-selective method with a 
wide range of linearity (0.02 to 3876.00 μg in 1 ml of 
plasma) for carrying out qualitative pre-clinical studies. 
The width of the range is due to the nature of the 
operations (dose adjustment and evaluation of the 
response linearity). Use of an internal standard ensured 
minimization of sample preparation errors and 
improved the accuracy of the determination. Since the 
pre-clinical studies in animals involve a large number of 
control points that need to be analyzed strictly in a 
particular analytical cycle, the method used a simple 
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and express sample preparation – protein precipitation 
with acetonitrile, followed by ultrasound extraction [9, 
10, 11]. To ensure a satisfactory sample purity and 
stable detection, the method of chromatographic 
separation on an analytical column filled with sorbent 
Zorbax Eclipce XDB C18 was used.  
Chromatographic system suitability parameters. 
To determine the chromatographic system 
suitability, the solutions for calibration curve were 
analyzed, the solution at a concentration of 19.38 μg 
in 1.0 ml of plasma was chromatographed six times, 
the equation of the calibration curve was calculated, 
and the obtained amounts were subject to reverse 
recalculation. The chromatographic system was 
considered suitable when meeting the following 
generally accepted criteria [9]:  
– errors in the reverse recalculation should not 
exceed: for a point equal to the LLOQ not more than 
20%; for all other points – not more than 15%; 
– relative standard deviation of the ratio of 
C7070 peaks area to the internal standard peak areas 
calculated on 6 consecutive chromatograms of 
solution at a concentration of 19.38 μg in 1.0 ml of 
plasma should not exceed 7%; 
– C7070 peak asymmetry factor at a 
concentration of 19.38 μg in 1.0 ml of plasma and the 
internal standard should not exceed 2.2%; 
– signal-to-noise ratio for the C7070 peak in the 
chromatogram of solution equal to the LLOQ must 
be at least 10:1. 
Method validation. 
Validation of the method for quantification of 
С7070 in rat plasma was conducted in accordance with 
the Guidelines for the examination of medicines [5], as 
well as Guidelines for the validation of bioanalytical 
FDA [8] and EMA practices [7] under the following 
characteristics: selectivity (specificity) linearity, 
accuracy and precision (within a series and between 
series), the limit of quantification, the sample stability, 
the matrix effect and the transferable residue. 
Selectivity (specificity). 
To determine the selectivity (specificity) a pure 
rat plasma sample was analyzed, as well as pure 
plasma samples with the addition of the standard 
solutions C7070 and internal standard in the expected 
range of concentrations.  
The chromatograms of pure plasma samples 
showed no peaks with retention time corresponding 
to retention time of C7070 and the internal standard 
(Fig. 1 (A-B)). 
 
  
С7070 Internal Standard 
A) Representative chromatogram of pure rat plasma. 
  
С7070 Internal Standard 
B) Representative chromatogram of the solution for calibration curve. 
 
Figure 1. Representative chromatograms in determining the selectivity. 
 
Transferable residue. 
To determine the presence of transferable 
residue the pure sample of rat plasma was analyzed 
after administration of maximum concentration 
solution (solution for calibration curve, level 7).  
The chromatograms of pure plasma samples after 
administration of maximum concentration solution 
showed no peaks with retention time corresponding to 
retention time of C7070 and the internal standard. This 
was achieved by satisfactory flushing of the input unit 
(syringe and needle were flushed with a 3 ml solution of 
water, acetonitrile, methanol, isopropanol and formic 
acid in a volumetric ratio of 24:25:25:25:1 prior to each 
administration). 
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Matrix Effect 
The said indicator was studied in six samples of 
biological matrix from different donors. The values of 
the coefficient of variation (CV) of the normalized 
matrix factors for six different rat matrices on the lower 
and upper concentration levels did not exceed 15%. The 
calculation of the normalized matrix factor is presented 
in Table 1. None of the results exceeds allowable limits. 
Table 1 
Determination of the normalized matrix factor in rat plasma. 
Solution Si0 Sis0 Si Sis 
Normalized  
matrix factor 
СV, 
% 
Acceptance Criteria 
LQC 
1286284 3328954 1398451 3288954 0.94 
14.1 
NMT 15 % 
1326741 3326544 1398754 3326841 0.95 NMT 15 % 
1358744 3421587 1339587 3521478 1.05 NMT 15 % 
1385655 3321478 1346744 3658421 1.08 NMT 15 % 
1258741 3185647 1828974 3268741 0.71 NMT 15 % 
1247841 3125877 1389751 3654871 1.05 NMT 15 % 
UQC 
112254871 3236544 143528974 3265471 0.83 
5.1 
NMT 15 % 
112684512 3328741 146875421 3388744 0.84 NMT 15 % 
123654123 3265877 144658971 3326952 0.84 NMT 15 % 
122657458 3128741 143289568 3297451 0.84 NMT 15 % 
119547877 3326877 144651847 3544326 0.90 NMT 15 % 
120745216 3184544 141286544 3641288 0.94 NMT 15 % 
 
Limit of Quantitation (LOQ): 
To find LOQ, a series of dilutions was prepared 
(from 1 to 25 ng in 1 ml of plasma). Based on the 
obtained results, the concentration with the signal/noise 
ratio for C7070 peak 10 and a coefficient of variation 
(CV) between six parallel definitions of not more than 
10% was selected. LOQ was 20 ng in 1 ml of plasma.  
Linearity 
According to the obtained values, the calibration 
curve was constructed, shown in Fig. 2. To assess the 
acceptability of the obtained values the reverse 
calculation of C7070 amounts from those entered by 
the equation of the calibration curve was performed. 
None of the values exceeded the allowable limits (for 
LOQ not more than 20%; for all other points – not 
more than 15%). Thus, the linear range of the method 
was 0.020 – 3876.0 μg in 1 ml of plasma. 
 
Figure 2. The linear dependence of peak area С7070 on its concentration normalized to the internal standard.  
 
Accuracy and precision (within a series and 
between series). 
Accuracy and precision of the method was 
evaluated on rat plasma samples with the addition of 
known quantities of C7070 at four concentration 
levels (LLOQ, LQC, MQC and UQC), which were 
prepared separately from the solutions prepared to 
confirm the linearity of the method. Each level was 
prepared five-fold. The accuracy was expressed: 
within the series, as a percentage of a nominal 
content of C7070 (Recovery) and between the series 
in the form of CV of the obtained values for each 
level on different days, in percentage. The precision 
was expressed with CV between parallel 
determinations of each concentration level within the 
series, in percentage.  The results are presented in 
Tables 2-3. 
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Table 2 
The accuracy (between the series) of the determination of С7070 in rat plasma. 
 
Solution 
Caver., μg/ml Caver., μg/ml Caver., μg/ml Caver., μg/ml СV,
% 
Acceptance 
criterion 
 cycle 1 cycle 2 cycle 3 cycle 4 
LLOQ 0.0216 0.0199 0.0211 0.0209 3.5 NMT 20 % 
LQC 0.1899 0.1934 0.1904 0.1905 0.8 NMT 15 % 
MQC 19.0575 18.9885 18.5546 19.4093 1.8 NMT 15 % 
UQC 1839.50 1945.11 1861.32 1889.58 2.4 NMT 15 % 
 
Table 3 
The accuracy and precision (within the series) of the determination of С7070  in rat plasma. 
 
Solution 
concentrati
on level 
 
Cycle 1 Cycle 2 Cycle 3 Cycle 4 
Cintr, 
µg/mL 
Recovery, % СV, % 
Reco-
very, % 
СV, % 
Reco-
very, % 
СV, % 
Recove-
ry, % 
СV, % 
LLOQ 0.0205 
117.5 
9.7 
81.9 
10.2 
106.2 
4.7 
98.2 
8.4 
113.1 100.3 102.2 102.9 
95.9 106.8 98.4 99.6 
106.3 103.1 98.1 99.3 
94.3 92.6 109.2 106.1 
LQC 0.1938 
99.3 
9.0 
99.5 
3.3 
103.9 
6.5 
106.3 
3.3 
100.2 100.5 95.8 87.4 
110.6 100.3 101.3 93.7 
87.3 103.8 88.2 90.8 
92.5 94.7 101.9 98.8 
MQC 19.38 
100.7 
3.7 
101.6 
3.6 
95.1 
6.6 
96.7 
5.9 
97.6 100.7 99.6 99.1 
97.3 94.4 84.9 108.4 
93.4 99.1 99.3 99.6 
102.8 94.0 99.8 95.0 
UQC 1938.0 
102.7 
5.0 
101.1 
6.0 
92.9 
5.2 
99.2 
6.7 
93.3 107.3 102.7 97.4 
92.8 102.6 98.9 100.5 
95.6 90.8 89.9 106.0 
90.2 100.1 95.7 105.1 
 
Solution stability. 
Stability of the solutions was assessed on two 
criteria – stability upon analysis in the automatic  
 
dispenser and stability at defreezing/freezing. 
The results are presented in Tables 4-5. 
Table 4 
Solution stability upon freezing/defrosting. 
 
Solution 
Caver, μg/ml Caver, μg/ml Caver, μg/ml Caver, μg/ml 
СV,% 
Acceptance 
Criterion 
 cycle 0 
cycle 1 
of freezing 
cycle 2 
of freezing 
cycle 3 
of freezing 
LQC 0.0216 0.0202 0.0238 0.0206 7.5 NMT 15 % 
UQC 1839.50 1842.88 1857.321 1947.99 2.7 NMT 15 % 
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Table 5 
Solution stability upon storage in the autosampler 
Solution 
Caver, μg/ml Caver, μg/ml Caver, μg/ml 
СV,% Acceptance Criterion 
0 hours of storage  8 hours of storage 16 hours of storage 
LQC 0.0216 0.02031 0.01978 4.5 NMT 15 % 
UQC 1839.50 1799.31 1899.48 2.7 NMT 15 % 
 
Representative chromatograms of both C7070 
and the internal standard (fabomotizole) at a MQC 
concentration in rat plasma (19.38 μg in 1 ml of rat 
plasma) are shown in Fig. 3. 
 
  
  
 
Figure 3. Chromatography and mass spectra of both С7070 and internal standard (fabomotizol) in rat plasma. 
 
Thus, the developed method of 
quantification of C7070 in rat plasma by high-
performance liquid chromatography with mass 
spectrometry is easy to implement, meets the 
requirements of the validation characteristics, 
and ensures reliable and accurate determination 
of C7070 in rat plasma in the concentration 
range of 0.02 μg/ml to 3876.00 μg/ml. 
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